Regional Dermatology Practices Are Quietly Selling to PE Rollups

The Quiet Consolidation Happening in Exam Rooms Across America

Across suburban strip malls and mid-sized city medical buildings, dermatology practices that have operated independently for decades are signing acquisition deals with private equity-backed platforms. The transactions are rarely announced with fanfare. A practice of four or five physicians, built over twenty years by a single founder, sells to a regional dermatology group that is itself backed by a PE firm, and within months the waiting room has new branding, the billing department has moved to a centralized office, and the founding physician is working on a three-year earn-out contract they helped negotiate but may not fully understand.

This consolidation wave has been building for several years, but it accelerated noticeably after interest rates began climbing and PE firms looked to deploy dry powder into recession-resistant healthcare verticals. Dermatology checks nearly every box that private equity looks for: predictable cash flow, high patient retention, a mix of insurance-reimbursed medical visits and out-of-pocket cosmetic procedures, and a physician workforce that skews toward solo or small-group ownership. The result is a market where independent dermatology practices are becoming rarer, and where the physicians who built them are often the last to understand the full implications of what they just signed.

Why Dermatology Became a PE Target

The specialty’s financial profile is unusually attractive by healthcare standards. A dermatology practice generates revenue from multiple streams simultaneously – medical dermatology covered by insurance, Mohs surgery, and cosmetic procedures like Botox, fillers, and laser treatments that patients pay for directly. That cosmetic revenue is particularly appealing because it carries no reimbursement risk. Insurance companies cannot cut rates on a $600 filler appointment. This hybrid billing model gives dermatology platforms a buffer that most other specialties simply do not have.

The supply side also favors consolidators. Dermatology has one of the most competitive residency matches in medicine, which means the physician pipeline is intentionally narrow. There are not enough dermatologists to meet demand, and the ones entering practice today often carry significant medical school debt and face the administrative burden of running a business they were never trained to run. Selling to a platform removes that burden. The pitch is straightforward: keep practicing medicine, give up ownership and some autonomy, and receive a check that likely exceeds what you could have earned by holding on another decade.

What the pitch does not always make clear is the structure of that check. Most transactions are structured with a combination of upfront cash and equity rolled into the acquiring platform. The equity portion only pays out if the platform itself sells, typically to a larger PE firm or a strategic acquirer. Physicians who roll equity are effectively betting on a second transaction happening at a higher valuation within five to seven years. Some of those bets pay off well. Others do not.

What Changes After the Sale

The immediate post-acquisition period tends to look reassuring. Leadership at PE-backed platforms typically promises operational support, centralized billing, group purchasing discounts on supplies, and marketing resources that a small independent practice could never afford alone. For the first year, many acquired physicians report genuine improvements in administrative workload. The paperwork that consumed evenings is now handled by a team somewhere else.

The friction usually appears later, once the platform has completed enough acquisitions to begin standardizing operations. Scheduling protocols change. Patient visit times shorten. Staff who were hired by the founding physician and who knew long-term patients by name are replaced or reassigned as HR functions centralize. Physicians who sold find themselves operating within productivity targets they agreed to in the contract but did not fully model out against their actual practice patterns. A dermatologist who built a reputation on unhurried, thorough skin cancer screenings may find that the platform’s per-day visit targets are incompatible with that approach.

The Rollup Math and Its Pressure Points

PE-backed dermatology rollups operate on a specific financial logic. The acquiring firm pays a certain multiple of EBITDA to buy individual practices, then bundles them into a larger platform that commands a higher multiple when sold to the next buyer. The arbitrage between the acquisition multiple and the exit multiple is where the return is made. This works as long as the platform can demonstrate growth – more locations, more revenue, tighter margins. That pressure to grow does not disappear after the acquisition closes. It intensifies.

To justify higher exit multiples, platforms need to show that the practices they bought are performing better under their management than they did independently. That performance is measured financially, which creates a direct tension with clinical decision-making. A dermatologist who wants to spend time counseling a patient on sun protection is generating no additional revenue during that conversation. A platform optimized for EBITDA margin sees that time differently than the physician does.

This dynamic is already playing out in states with higher PE dermatology penetration. Physicians within acquired groups describe informal pressure to increase patient volume and to upsell cosmetic procedures to patients who came in for medical visits. Whether that upselling is genuinely in patients’ interest depends on the specific situation, but the incentive structure makes it a persistent pressure rather than an individual choice. Regulators in several states have begun examining whether PE ownership structures in specialty medicine are influencing clinical recommendations in ways that traditional medical ethics frameworks were not designed to address.

The consolidation also has downstream effects on independent practices that choose not to sell. As PE-backed platforms expand, they recruit aggressively from the same local physician pool. A four-person independent practice loses an associate to a platform offering a higher base salary and student loan assistance – benefits the independent group cannot match without the capital advantage that comes with PE backing. The competitive pressure is not just about patients or market share. It is about whether independent practices can continue to attract and retain the physicians they need to stay viable. That is a harder problem to solve than any billing upgrade, and it does not come with an earn-out clause or a buyout check when the going gets tough.